About the Clinical Trials Activity initiative
The Clinical Trials Activity initiative will provide $750 million over 10 years between 2022-23 and 2031-32 to increase clinical trial activity in Australia.
The initial focus of this initiative was on clinical trials addressing rare cancers, rare diseases, and unmet needs, and on bringing investigator-led international clinical trials to Australia.
The initiative’s focus has now been expanded to enable funding of research projects focused on any disease or condition that meets the objective specified in each grant opportunity.
Why it is important
This initiative is important because it supports clinical trials that test the effectiveness of therapies and treatments and create the evidence needed to improve clinical practice.
The objective of this initiative is to increase clinical trial activity in Australia to:
- improve the evidence base supporting clinical care
- help patients access trials relevant to their health circumstances
- enable researchers to bring international trials to Australian patients.
Meeting our objectives
We will monitor the initiative in accordance with the principles and approach detailed in the MRFF Monitoring, evaluation and learning strategy.
Who we work with
The Medical Research Future Fund (MRFF) funds the initiative.
Our Health and Medical Research Office oversees this and other MRFF initiatives.
The National Health and Medical Research Council (NHMRC) administers this initiative.
Apply for funding
View the MRFF grants calendar to see which grants are open, when applications close and when we expect to award funding.
Register with GrantConnect to receive notifications about future funding opportunities under this initiative.
Monitoring, evaluation and learning
We have engaged the Institute for Evidence-Based Healthcare (IEBH), Bond University, to evaluate this initiative.
IEBH will carry out a desktop review, survey, and consult with stakeholders, to assess progress made under the initiative. IEBH will also look at the initiative’s progress in meeting objectives set out in the MRFF 10-year Investment Plan.
The findings are due mid-2023 and will support future clinical trial activity through the MRFF.
More information is available from MRFF.firstname.lastname@example.org.
For more information, contact us.